---
layout: default
title: Alpha -Tocopherol Dl- Ascorbic Acid Cholecalcifero
parent: 僅模型預測 (L5)
nav_order: 246
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Dl- Ascorbic Acid Cholecalcifero
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin Complex: No TxGNN Predictions Available

---

## One-Sentence Summary

This candidate is a 14-component multivitamin/mineral complex (including vitamins A, B1, B2, B3, B6, B9, B12, C, D3, E, plus copper, magnesium, fluoride, and levomefolic acid), with no approved indication on record in Taiwan.
The TxGNN model returned **no predicted new indications** for this combination, and no supporting clinical trials or publications were identified.
This candidate cannot proceed to repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No record (not marketed in Taiwan) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; no predictions generated) |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate; therefore, a mechanism-to-indication bridging analysis cannot be performed.

The drug entry is a complex mixture of 14 active ingredients:
- **Fat-soluble vitamins**: DL-α-Tocopherol (Vit E), Cholecalciferol (Vit D3), Vitamin A
- **Water-soluble vitamins**: Ascorbic Acid (Vit C), Thiamine HCl (Vit B1), Riboflavin (Vit B2), Niacinamide (Vit B3), Pyridoxine HCl (Vit B6), Folic Acid, Levomefolic Acid, Cyanocobalamin (Vit B12)
- **Minerals**: Cupric Sulfate (copper), Magnesium Oxide, Sodium Fluoride

The inclusion of levomefolic acid (the active methylated form of folate) alongside standard folic acid suggests this is likely a **prenatal or therapeutic-grade multivitamin** formulation. However, because TxGNN operates on single DrugBank entities and this combination lacks a unified DrugBank ID, the model was unable to map the mixture to the knowledge graph and therefore generated no repurposing candidate scores.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no predicted indications for this 14-component mixture, most likely because no unified DrugBank ID exists for the combination entry, preventing knowledge-graph traversal. Without a prediction score or supporting evidence, there is no repurposing hypothesis to evaluate.

**To proceed, the following is needed:**

- **Decompose and re-query individually**: Identify the primary active ingredient (e.g., Levomefolic Acid or Cholecalciferol) and submit each as a separate TxGNN query to obtain individual drug-level predictions.
- **Assign DrugBank IDs per component**: Map each of the 14 ingredients to its respective DrugBank entry so the knowledge graph can be traversed.
- **Clarify the intended formulation category**: Confirm whether this is a prenatal vitamin, general nutritional supplement, or therapeutic-grade preparation, as the indication context differs substantially.
- **Obtain Taiwan FDA package insert**: Retrieve the TFDA product monograph to populate safety warnings and contraindications (currently unavailable).
- **Re-run the full evidence pipeline** after individual components are resolved.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

